Expected approval of gene therapy for treatment of spinal muscular atrophy is set to emerge as the game-changer in global spinal muscular atrophy therapeutics market. FDA approval of Zolgensma, experimental gene therapy by Novartis is awaited in first half of the year 2019. It would provide a cost-effective alternative to expensive Spinraza therapy.
The report “Global Spinal Muscular Atrophy Market (By Drugs – Spinraza, Branaplam & Reldesemtiv; By Region – North America, Asia Pacific & Europe) Market Outlook 2025” provides an in-depth analysis of global spinal muscular atrophy market across major therapeutics such as Spinraza, Branaplam & Reldesemtiv. Market outlook for spinal muscular atrophy market overall as well as across various sub-segments has been provided for the period 2019-25. Regional analysis is done across major markets in North America, Europe and Asia Pacific.
The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities in global spinal muscular atrophy market. The report has been segmented as following:-
Market Segments
• Spinraza
• Branaplam
• Reldesemtiv
Geographical Coverage
• North America - The US
• Europe
• Asia Pacific
Key Vendors
• Biogen Inc.
• Cytokinetics Inc.
• AveXis Inc.
• F. Hoffman –La Roche
• Ionis Pharmaceuticals Inc.
1. Executive Summary
2. Research Methodology
3. Spinal Muscular Atrophy
3.1 Overview
3.1.1 Types of Diseases
3.1.2 Symptoms of SMA
3.1.3 Diagnosis of SMA
3.2 Therapy for SMA
4. Market Analysis
4.1 Market Sizing (Actual & Forecasted)
4.1.1 Market Sizing by Value (Actual & Forecasted)
4.1.2 Market Sizing by Volume (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by Disease Type
4.2.2 Market Share by Route of Administration
4.2.3 Market Share by Region
4.2.4 Market Share by Patient Age-Group
5. Market Segmentation by Drugs
5.1 Spinraza
5.1.1 Overview
5.1.2 Market Sizing (Actual & Forecasted)
5.2 Branaplam
5.2.1 Overview
5.3 Reldesemtiv
5.3.1 Overview
5.3.2 Market Sizing (Actual & Forecasted)
6. Regional Analysis
6.1 North America - The US
6.1.1 Market Sizing by Value (Actual & Forecasted)
6.1.2 Market Sizing by Volume (Actual & Forecasted)
6.1.3 Market Share by Treatment
6.1.4 Market Share by Prevalence of Disease
6.2 Europe
6.2.1 Market Sizing by Value (Actual & Forecasted)
6.2.2 Market Sizing by Volume (Actual & Forecasted)
7. Market Dynamics
7.1 Industry Trends & Developments
7.1.1 Gene Therapy for Treatment of Spinal Muscular Atrophy
7.1.2 MRI for SMA Detection
7.1.3 Strategic Collaboration to Develop Novel Small Molecule RNA Splicing Modifiers
7.2 Growth Drivers
7.2.1 Rising Incidences of Spinal Muscular Atrophy (SMA)
7.2.2 Government Impetus
7.2.3 Growing Consumer Awareness
7.2.5 Increasing Funding for R&D
7.3 Challenges
7.3.1 High Cost of Therapy
7.3.2 Low Market Penetration of Drug Therapy
8. Competitive Landscape
9. Company Profiles
9.1 Biogen Inc.
9.2 Cytokinetics, Inc.
9.3 AveXis, Inc.(Novartis AG)
9.4 F. Hoffmann-La Roche AG
9.5 Ionis Pharmaceuticals, Inc.
List of Tables
Table 1: SMA Prevalence in the US
Table 2: SMA Prevalence in Europe
Table 3: Spinal Muscular Atrophy (SMA) Drugs by Clinical Safety Profile
Table 4: Spinal Muscular Atrophy (SMA) Drugs Patient Population and Developmental Status
Table 5: Comparative Analysis of Spinal Muscular Atrophy (SMA) Drugs
Table 6: Comparison of Forecasted Revenue of Leading Companies in SMA Market
Table 7: Biogen Inc. Drug – Spinraza Sales, 2016-27E (US$ Millions)
Table 8: Cytokinetics, Inc. Drug - Reldesemtiv Clinical Trial
Table 9: Avexis Inc. SMA Existing Drugs
Table 10: Avexis Inc. SMA Drugs Pipeline
List of Figures
Figure 1: Rockville Research – Research Methodology
Figure 2: Classification of Spinal Muscular Atrophy
Figure 3: Diagrammatic Representation of SMN1 Gene Therapy
Figure 4: Therapeutic Intervention in Spinal Muscular Atrophy (SMA)
Figure 5: Global Spinal Muscular Atrophy Market Size by Value, 2016-25E (US$ Millions)
Figure 6: Global Spinal Muscular Atrophy Market Size by Volume, 2016-25E
Figure 7: Global Spinal Muscular Atrophy Market Share by Disease Type (2018)
Figure 8: Global Spinal Muscular Atrophy Market Share by Route of Administration (2018)
Figure 9: Global Spinal Muscular Atrophy Market Share by Region (2018)
Figure 10: Global Spinal Muscular Atrophy Market Share by Patient Age-Group (2018)
Figure 11: Global SMA Drug – Spinraza Net Sales, FY2013-FY2025E (US$ Billions)
Figure 12: Global SMA Drug – Reldesemtiv Net Sales, FY2013-FY2018E (US$ Billions)
Figure 13: The US Spinal Muscular Atrophy (SMA) Market Size by Value, 2016-25E (US$ Millions)
Figure 14: The US Spinal Muscular Atrophy (SMA) Market Share by Treatment, 2018 & 2025E
Figure 15: The US Spinal Muscular Atrophy (SMA) Prevalence by Type of Disease (2018)
Figure 15: Europe Spinal Muscular Atrophy (SMA) Market Size by Value, 2016-25E (US$ Millions)
Figure 16: Spinal Muscular Atrophy (SMA) Incidences by Nations (2018)
Figure 17: Spinal Muscular Atrophy (SMA) Drugs Approved & in Clinical Trials
Figure 18: Spinal Muscular Atrophy (SMA) Drugs Competitive Portfolio
Figure 19: Biogen Inc. SMA Drugs Clinical Pipeline
Figure 20: Biogen Inc. Revenue by Business Segment (FY2018)
Figure 21: Biogen Inc. Net Sales, FY2013-FY2018 (US$ Billions)
Figure 22: Cytokinetics Inc. Revenue by Business Segment (FY2018)
Figure 23: Cytokinetics Inc. Net Sales, FY2013-FY2018 (US$ Billions)
Figure 24: Novartis AG Revenue by Business Segment (FY2018)
Figure 25: Avexis Inc. Net Sales, FY2013-FY2018 (US$ Billions)
Figure 26: F. Hoffmann-La Roche AG Revenue by Business Segment (FY2018)
Figure 27: F. Hoffmann-La Roche AG Net Sales, FY2013-FY2018 (US$ Billions)
Figure 28: Ionis Pharmaceuticals, Inc. Revenue by Business Segment (FY2018)
Figure 29: Ionis Pharmaceuticals, Inc. Net Sales, FY2013-FY2018 (US$ Billions)
Biogen Inc., Cytokinetics Inc., AveXis Inc., F. Hoffman –La Roche & Ionis Pharmaceuticals Inc.
*If Applicable.
Links
[1] https://www.marketresearchreports.com/countries/north-america[2] https://www.marketresearchreports.com/countries/europe[3] https://www.marketresearchreports.com/diseases[4] https://www.marketresearchreports.com/diagnostics[5] https://www.marketresearchreports.com/country-overview-pharma-healthcare[6] https://www.marketresearchreports.com/pharma-healthcare